Stockpile bird flu vaccine now

February 16, 2005

GOVERNMENTS should consider stockpiling vaccine against H5N1 bird flu now, before a pandemic starts, a World Health Organization report out next month will advise. The change in policy reflects growing fears that an H5 pandemic is likely, and that there will not be time to produce much vaccine once it starts. "When we realised H5N1 is not going to be eradicated in poultry in Asia for at least another couple of years, that made the risk of H5 much higher," Klaus Stöhr, head of the WHO's influenza team, told New Scientist.

The US has already contracted manufacturers to make 4 million doses, while at a meeting at WHO headquarters in Geneva last week Italy and France said they plan to stockpile 2 million doses each. But in a world of over 6 billion people that is nowhere near enough to make a significant difference, as Stöhr points out. "This is an option only for affluent countries, and then for a fraction of their population," he says. "It won't change a lot at the global level."

Until now the WHO has said that a vaccine cannot be made until a pandemic starts, as only then can it be based on the exact strain of the virus responsible. "Normally there is no point stockpiling vaccine, because you don't know which flu will cause the next pandemic," Stöhr says. "It could be H7 or H9." But the failure to halt the H5N1 bird flu outbreaks in Asia, and the growing number of human cases (see Table), is changing minds. Recent findings also suggest that a stockpiled vaccine could provide some protection even if it does not exactly match the pandemic virus.

Experiments on animals at St Jude's Children's Hospital in Memphis, Tennessee, show that while previous exposure to similar strains may not stop them falling ill when infected with H5N1 flu, it can prevent them dying. What's more, people normally require two shots of a vaccine to make them immune to a strain of flu they have not encountered before. An H5 vaccine would prime people's immune systems, so they would need only one shot of a specific pandemic vaccine.

"My gut feeling is that if you're primed with H5, you'll respond better to the flu or to the real vaccine," says Tony Colegate of Chiron Vaccines in Liverpool, UK, who heads an international industry task force on pandemic flu. Such evidence has persuaded the experts that an H5 vaccine might help. Now the problem is making it.

So far, only half the planned US stockpile has been made, by Sanofi-Pasteur in the US. Chiron is to make the rest at a pilot factory in Liverpool that is licensed to handle the genetically engineered viruses required. But it cannot start until the problems with contamination that shut down the company's normal flu vaccine plant at the same site are cleared up. Without a dedicated factory, companies have only a two to three-month window between production runs of ordinary flu vaccine to make H5 vaccine. And they cannot even do that, Colegate says, unless someone will buy it. Then there is testing.

It is obviously impossible to find out in advance whether a vaccine will provide any protection against a pandemic strain. But it is possible to do safety tests and work out the dose needed to produce an immune response. Clinical trials of limited batches of H5 vaccine, based on the strain now circulating in Asia, are about to start in the US and are planned in Canada, Australia and Japan, all with government funding. Because these vaccines have been made at different plants using different production methods they must be tested separately.

No European governments have pledged funding for clinical trials even though most of the world's flu vaccine is made in Europe. Not everybody is convinced that spending money on testing and stockpiling an H5 vaccine is worthwhile. Albert Osterhaus of Erasmus University in Rotterdam, the Netherlands, thinks money would be better spent on stockpiling antiviral drugs, as the WHO has long recommended.

But the capacity for manufacturing antivirals is limited, and there is also no guarantee that existing drugs will work against a pandemic strain. Other leading experts think the threat is so serious that we should be doing everything we can to prepare.
-end-
This article appears in New Scientist issue: 19 FEBRUARY 2005

Written by DEBORA MACKENZIE

PLEASE MENTION NEW SCIENTIST AS THE SOURCE OF THIS STORY AND, IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO: http://www.newscientist.com

"These articles are posted on this site to give advance access to other authorised media who may wish to quote extracts as part of fair dealing with this copyrighted material. Full attribution is required, and if publishing online a link to www.newscientist.com is also required. Advance permission is required before any and every reproduction of each article in full - please contact celia.thomas@rbi.co.uk. Please note that all material is copyright of Reed Business Information Limited and we reserve the right to take such action as we consider appropriate to protect such copyright."

New Scientist

Related Pandemic Articles from Brightsurf:

Areas where the next pandemic could emerge are revealed
An international team of human- and animal health experts has incorporated environmental, social and economic considerations -- including air transit centrality - to identify key areas at risk of leading to the next pandemic.

Narcissists love being pandemic 'essential workers'
There's one group of essential workers who especially enjoy being called a ''hero'' during the COVID-19 pandemic: narcissists.

COVID-19: Air quality influences the pandemic
An interdisciplinary team from the University of Geneva and the ETH Z├╝rich spin-off Meteodat investigated possible interactions between acutely elevated levels of fine particulate matter and the virulence of the coronavirus disease.

People who purchased firearms during pandemic more likely to be suicidal
People who purchase a firearm during the pandemic are more likely to be suicidal than other firearm owners, according to a Rutgers study.

Measles outbreaks likely in wake of COVID-19 pandemic
Major measles outbreaks will likely occur during 2021 as an unexpected consequence of the COVID-19 pandemic, according to a new academic article.

The COVID-19 pandemic: How US universities responded
A new George Mason University study found that the majority of university announcements occurred on the same day as the World Health Organization's pandemic declaration.

Researchers find evidence of pandemic fatigue
A new study from the USC Leonard Davis School of Gerontology shows that the behavioral responses to COVID-19 differed by age.

Excessive alcohol consumption during the COVID-19 pandemic
The full impact of COVID-19 on alcohol use is not yet known, but rates have been rising during the first few months of the pandemic.

How fear encourages physical distancing during pandemic
Despite guidelines plastered on the walls and floors of grocery and retail stores encouraging customers to maintain six-feet of physical distance during the pandemic, many do not.

COVID-19 pandemic and $16 trillion virus
This Viewpoint aggregates mortality, morbidity, mental health conditions, and direct economic losses to estimate the total cost of the pandemic in the US on the optimistic assumption that it will be substantially contained by the fall of 2021.

Read More: Pandemic News and Pandemic Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.